Objective To establish a mouse model for treating immune checkpoint inhibitor associated colitis and explore the effect of Babao Dan on immune checkpoint inhibitor associated colitis in mice. Methods To divide 36 C57BL/6J mice into four groups: blank group (CON group), saline group (DSS group), saline+inhibitor group (MOD group), and saline+inhibitor+Babao Dan group (BBD group), with 5 mice in each group by a random number table. Results The CMO group showed the epithelial cell necrosis and shedding, extensive edema, thinning of the intestinal wall, disordered glandular arrangement, severe ulcer symptoms, and extensive infiltration of inflammatory cells in the mucosal layer compared with the CON group. The colonic epithelial conditions and ulcer symptoms showed that the BBD group had reduced symptoms, moderate infiltration of inflammatory cells in the mucosal muscle layer, and no severe ulcer symptoms between the DSS and BBD group mice. Compared with the CON group,The weight, colon length, and colon coefficient of mice in other groups, decreased or became shorter. However. The weight, colon length, and colon coefficient of mice in the BBD group decreased or became shorter than in the MOD group and DSS group. The spleen coefficient of mice in the MOD group and DSS group decreased or became shorter compared in the CON group. The BBD group mice showed similar weight loss scores and stool shape score compared with the DSS group, while the fecal blood score and DAI score showed a decreasing trend. The mice of BBD group showed a decreasing trend in weight loss score, stool shape score, rectal bleeding score, and DAI score, as well as a decreasing trend in rectal bleeding score and DAI score compared with the MOD group. Conclusions This article constructs an immune checkpoint inhibitor associated colitis model by using immune checkpoint inhibitors, and feeding Baodan can significantly alleviate the symptoms of immune checkpoint inhibitor associated colitis in mice.
Key words
Babao Dan /
Immune checkpoint inhibitors /
Colitis /
Influence
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 孟肖娜,孙旭,刘怀民. 免疫检查点抑制剂相关结肠炎的研究进展[J]. 实用医学杂志,2024,40(9):1314-1319.
[2] 谭蓓,王汉萍,李玥,等. 免疫检查点抑制剂相关结肠炎八例临床特征分析[J]. 中华消化杂志,2021,41(5):330-335.
[3] Reiko YY,Yasushi ST,Fumika NK,et al.Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events:a case series[J]. Clin J Gastroenterol,2023,16(6):842-847.
[4] 郑雅丹,李岭,庞智. 免疫检查点抑制剂及其相关性结肠炎的研究进展[J]. 胃肠病学,2020,25(1):51-54.
[5] Liu,YX,Wu,W.Cardiovascular immune-related adverse events:Evaluation,diagnosis and management[J].Asia Pac J Clin Oncol,2020,16(4):232-240.
[6] 胡志强,门奋勇,刘冬. 接受免疫检查点抑制剂治疗所致免疫相关不良事件与晚期原发性肝癌患者疗效的关联分析[J]. 肝脏,2023,28(8):935-937.
[7] 郭宇扬,王嫣琦,白宇,等. 免疫检查点抑制剂相关结肠炎的发病机制[J]. 临床医学进展,2022,12(10):8888-8893.
[8] 柯樱,赵亚红.八宝丹的临床应用研究进展[J].中成药,2017,39(2):386-389.
[9] 谭蓓,唐颢,徐燕,等. 鼠李糖乳杆菌对免疫检查点抑制剂相关小鼠结肠炎的保护作用及其机制[J]. 中华医学杂志,2020,100(42):3332-3337.
[10] 尤雯. 维生素D3联合鼠李糖乳杆菌对肿瘤免疫治疗相关结肠炎的保护作用及其机制研究[D]. 北京:中国医学科学院,清华大学医学部,北京协和医学院,2022.
[11] Matsuo N,Azuma K,Kojima T,et al.Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy[J]. Invest New Drug.,2021,39(4):1150-1158.
[12] 徐天铭. 促炎因子和益生菌调控Wnt/β-catenin信号通路相关机制研究[D]. 北京:北京协和医学院,中国医学科学院,清华大学医学部,北京协和医学院中国医学科学院,2016.
[13] 杨峰. 免疫检查点抑制剂不良反应的研究进展[J]. 中国肿瘤生物治疗杂志,2022,29(11):989-994.
[14] Gonzalez MI.,Sanchez BL.,Martin VJ.,et al.Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy:a 3-year study of 102 cases from a single centre[J]. Clin Exp Rheumatol,2021,39(3):612-620.
[15] Yamaguchi AT,Saito YK,Narumi KY,et al.Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy[J]. J Cancer Res Clin Oncol,2023,149(4):1659-1666.
[16] 赵洪睿. 免疫检查点抑制剂治疗晚期恶性肿瘤相关免疫不良事件的Meta分析与系统评价[D]. 石家庄:河北医科大学,2023.
[17] Sangro B,Chan SL,Meyer T,et al.Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma[J]. J Hepatol,2020,72(2):320-341.
[18] 赵娜. 丝氨酸蛋白酶抑制因子Spink7促进炎症消退的作用与机制探索——基于小鼠创面愈合与结肠炎模型的实验研究[D]. 重庆:陆军军医大学,2021.
[19] Cao R,Wu C,Lv Y,et al. Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma[J]. Oncol Lett,2023,25(2):Article. 55.
[20] Leung BW Wan G.,Ni YN.,et al.Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors:A multi-hospital cohort study[J]. J Am Acad Dermatol,2023,88(6):1265-1270.
[21] 李宪美,曾来凤,黄彬等. 基于斑马鱼模型探讨八宝丹对阿奇霉素所致心肌损伤的保护作用及机制[J]. 中国实验动物学报,2024,32(5):557-565.
[22] Gui MX,Huang B,Peng J,et al.BaBao Dan Allevistes 5-Fluorouracil.induced intestinal Damage via Wnt/β-Catenin Pathwsy[J]. Chin Jintegr Med,2022,28(11):1000-1006.
PDF(1591 KB)
